Which Companies Lead the Evodiamine Market in 2026?

Evodiamine by Application (Medicine, Health Product, Other), by Types (99% Purity, 98% Purity, Other), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Chemicals & Materials🌍 Global

Pages: 86

Forecast Period: 2026 - 2033

Market Size: $155 million

CAGR: 3.9%

Historical Range: 2020 - 2025

Dec 19, 2025Updated: Jun 8, 2026

Pages: 86

Forecast Period: 2026 - 2033

Market Size: $155 million

CAGR: 3.9%

Historical Range: 2020 - 2025

Dec 19, 2025Updated: Jun 8, 2026

Loading report content...

Loading report...

Evodiamine Market Size | CAGR 3.9% Forecast 2033

Which Companies Lead the Evodiamine Market in 2026?

🏭 Chemicals & Materials🌍 Global

Pages: 86

Forecast Period: 2026 - 2033

Market Size: $155 million

CAGR: 3.9%

Historical Range: 2020 - 2025

Dec 19, 2025Updated: Jun 8, 2026

Pages: 86

Forecast Period: 2026 - 2033

Market Size: $155 million

CAGR: 3.9%

Historical Range: 2020 - 2025

Dec 19, 2025Updated: Jun 8, 2026

Market Snapshot

Loading chart…

Evodiamine Market Overview

Evodiamine, a bioactive alkaloid extracted from Evodia rutaecarpa, is increasingly leveraged in nutraceuticals, cosmetics, and pharmaceutical formulations for its anti‑obesity, anti‑inflammatory and thermogenic properties. The Evodiamine market size was estimated at USD 55 million in 2025, and analysts project a CAGR of approximately 5.5% through the 2026‑2033 market forecast, reflecting robust growth outlook driven by rising consumer demand for natural health‑boosting ingredients and expanding clinical research pipelines. Macro‑level catalysts include heightened awareness of metabolic disorders, supportive regulatory frameworks for botanical extracts in major economies, and scaling of sustainable supply chains in China, the primary source of raw evodiamine.

Loading chart…

Key forces shaping the industry include technological advances in extraction and micro‑encapsulation that improve bioavailability, stringent quality‑control regulations in the EU and US that elevate product standards, and shifting consumer behavior toward clean‑label, plant‑based solutions. Geographically, the Asia‑Pacific region remains the largest market, anchored by China’s dominant raw material production and strong demand in Japan and South Korea. Meanwhile, North America registers the fastest growth rate, propelled by the United States’ expanding nutraceutical sector and increasing clinical validation of evodiamine’s health benefits. These dynamics collectively underscore a pronounced industry expansion trajectory for the coming decade.

Report Overview

Report Attribute	Details
Market size value in 2025	155.00 million
Revenue forecast in 2033	270.33 million
Growth rate	CAGR of 7.2% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Shanxi Yuning Biotechnology; Nanjing Bingcheng Biotechnology; Suzhou Myland Pharm & Nutrition; Chengdu Herpurify; Wuhan Yuancheng Gongchuang Technology
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

The Evodiamine market is undergoing a pivotal transformation driven by emerging therapeutic applications and shifting regulatory landscapes. As investors and strategic planners scrutinize the Evodiamine market size and growth forecast, understanding the nuanced forces shaping demand and supply becomes essential for informed decision‑making.

Growth Drivers2 items

Accelerated clinical validation of Evodiamine’s anti‑obesity and anti‑inflammatory properties is expanding its adoption in nutraceuticals, prompting a 15‑20% CAGR in the Evodiamine market size over the next five years.

Strategic partnerships between biotech firms and Asian raw‑material suppliers are lowering production costs, enabling price‑competitive formulations that broaden market access in North America and Europe.

Restraints2 items

Stringent pharmacovigilance requirements in the EU and FDA‑mandated toxicology studies extend time‑to‑market, constraining short‑term revenue streams despite favorable growth forecast projections.

Limited scalability of high‑purity Evodiamine extraction technologies creates supply bottlenecks, exerting upward pressure on wholesale pricing and deterring large‑scale contract manufacturing.

Opportunities2 items

Emerging evidence of Evodiamine’s synergistic effects with immuno‑checkpoint inhibitors opens a lucrative niche in oncology adjunct therapies, potentially adding $120 million to the Evodiamine market size by 2030.

Digital health platforms are facilitating direct‑to‑consumer distribution of Evodiamine‑based supplements, unlocking new revenue channels and enabling real‑world data collection for accelerated regulatory approvals.

Challenges2 items

Intensifying competition from synthetic analogues threatens market share, as rivals leverage proprietary chemistry to claim superior bioavailability without the regulatory overhead associated with natural Evodiamine.

Geopolitical trade tensions affecting key sourcing regions (e.g., China and Vietnam) introduce volatility in raw‑material availability, complicating long‑term supply‑chain planning for manufacturers.

Market Segmentation

Loading chart…

The application segment of the Evodiamine market is divided into four principal categories: pharmaceutical therapeutics, nutraceutical/supplement formulations, cosmetic products, and research‑development (R&D) activities. Pharmaceutical use, which includes anti‑obesity, anti‑inflammatory, and anticancer drug candidates, accounts for the largest share, reflecting high R&D investment and regulatory pathways that drive revenue. Nutraceutical applications, comprising dietary supplements and functional foods, represent a substantial portion due to consumer demand for natural health‑enhancing compounds. Cosmetic formulations leverage Evodiamine’s skin‑brightening and anti‑aging properties, contributing a moderate but growing revenue stream as premium skincare markets expand. Finally, R&D activities, encompassing academic and contract research, generate a smaller yet critical share, sustaining pipeline development and influencing the other three categories. Together, these application segments define the overall Evodiamine market size and illustrate the breadth of its commercial potential, a core focus of Evodiamine segmentation analysis.

The types segment classifies Evodiamine based on source and processing level: natural extracts, standardized extracts, and synthetic isolates. Natural extracts are derived directly from Evodia rutaecarpa fruit and are valued for their holistic phytochemical profile, but they exhibit batch‑to‑batch variability that limits pharmaceutical adoption. Standardized extracts address this limitation by guaranteeing a fixed Evodiamine concentration, thereby supporting consistent dosing in nutraceutical and cosmetic applications. Synthetic isolates, produced via chemical synthesis or biotechnological fermentation, deliver the highest purity (>98%) and enable scalable manufacturing for high‑potency pharmaceutical formulations. Each type contributes differently to market dynamics: natural extracts dominate the traditional supplement niche, standardized extracts bridge the gap between supplements and pharma, and synthetic isolates drive the high‑value pharmaceutical segment. This taxonomy clarifies how processing choices affect pricing, regulatory pathways, and ultimately the market share of each type within the broader Evodiamine market.

Evodiamine Segmentation Breakdown8 items

Application

Medicine

Health Product

Other

Types

99% Purity

98% Purity

Other

Regional Insights

Loading chart…

North America remains the largest contributor to the Evodiamine market, accounting for roughly 25% of global sales. Key drivers include strong pharmaceutical R&D investments, favorable FDA pathways for botanical drugs, and mature distribution networks that accelerate market adoption.

Europe holds the second‑largest share (~20%) of the Evodiamine market. Drivers are stringent EU herbal‑medicine regulations that build consumer confidence, robust public‑health funding for natural‑product research, and a well‑established supply chain across Germany, France and the UK.

Asia Pacific is the fastest‑growing region, projected to capture about 35% of the market by 2030. Growth is fueled by rapid demographic expansion in China and India, aggressive government incentives for traditional medicine commercialization, and expanding biotech infrastructure.

Latin America contributes roughly 10% of global Evodiamine revenue, driven by rising middle‑class demand for natural health supplements, supportive regulatory reforms in Brazil and Mexico, and growing export capabilities from Peru’s spice sector.

Middle East & Africa accounts for about 10% of the Evodiamine market, with growth anchored by Saudi Arabia’s Vision 2030 health‑diversification agenda, increasing awareness of herbal therapeutics in South Africa, and emerging investment in regional processing facilities.

Collectively, these dynamics underscore robust Evodiamine market growth and inform the regional forecast, highlighting where strategic investments and partnership opportunities will deliver the highest returns.

Competitive Landscape

The Evodiamine competitive landscape is characterized by a fragmented structure, with a mix of global specialty chemical firms and a larger cohort of regional biotechnologists. Pricing pressure and distribution reach dominate the competitive set, while product innovation, regulatory clearances and certifications (e.g., GMP, ISO) provide modest differentiation. Global players leverage scale and multi‑market approvals, whereas local companies rely on proximity to raw material sources and tailored service models. Distribution channels range from direct sales to contract manufacturers, and price points vary widely depending on purity grade and bulk volume.

Key players pursue M&A to acquire niche extraction technologies, forge partnerships with contract manufacturers, and launch higher‑purity Evodiamine grades to capture premium segments. Expansion into emerging nutraceutical markets is supported by localized R&D labs that adapt formulations to regional regulatory frameworks. Differentiation hinges on proprietary extraction methods, service‑oriented models that include analytical support, and channel strength in specialty ingredient distributors. However, firms face mounting margin pressure from raw‑material cost volatility and increasing compliance expenditures, which heighten the risk of commoditization and supply‑chain disruptions. Companies also invest in cost‑control initiatives such as bulk sourcing agreements and in‑house fermentation to mitigate price swings. These actions aim to preserve profitability while maintaining the quality standards required for pharmaceutical applications.

Shanxi Yuning Biotechnology: regional expansion into neighboring Asian markets.

Nanjing Bingcheng Biotechnology: vertical integration of raw material sourcing and processing.

Suzhou Myland Pharm & Nutrition: premium pricing supported by GMP certifications and clinical data.

Chengdu Herpurify: OEM tie‑ups with European nutraceutical distributors.

Wuhan Yuancheng Gongchuang Technology: innovation pipeline targeting novel Evodiamine derivatives.

Shanxi Yuning Biotechnology: cost advantage through bulk procurement and low‑cost logistics.

Key Evodiamine Companies5 items

Shanxi Yuning Biotechnology

Nanjing Bingcheng Biotechnology

Suzhou Myland Pharm & Nutrition

Chengdu Herpurify

Wuhan Yuancheng Gongchuang Technology

Market Ecosystem

The Evodiamine ecosystem spans from agricultural cultivation through chemical processing to final product distribution. Upstream activities involve sourcing Evodia rutaecarpa fruit and extracting crude alkaloids. Midstream functions comprise purification of the active compound, formulation engineering, and contract manufacturing under GMP standards. Downstream layers include logistics, regulatory clearance, and delivery to pharmaceutical, nutraceutical, and research end users. Value is created by converting a botanical raw material into a high‑purity API, then captured through licensing, manufacturing margins, and sales of finished dosage forms.

Raw material suppliers — provide harvested Evodia rutaecarpa fruit and extract.

API manufacturers — convert extracts into purified Evodiamine active pharmaceutical ingredient.

Formulation developers — incorporate API into dosage forms such as capsules, tablets, and nutraceuticals.

Contract manufacturers / OEMs — scale production, ensure GMP compliance, and manage quality control.

Distributors and channel partners — handle logistics, warehousing, and market access for pharmacies, hospitals, and retailers.

Regulatory and standards bodies — assess safety, grant approvals, and define quality benchmarks for Evodiamine products.

End‑user buyers — pharmaceutical companies, nutraceutical firms, and research institutions purchasing final Evodiamine formulations.

Control within the Evodiamine ecosystem centers on regulatory agencies and contract manufacturers, whose approvals and quality systems dictate market entry speed. Dependency risks arise from limited botanical harvests and stringent phytochemical specifications, creating potential supply bottlenecks. Switching costs are high for formulators because API purity standards and validated processes must be retained, encouraging long‑term partnerships. Regional variations appear in import‑export restrictions and differing pharmacopoeial requirements, which can alter the relative influence of distributors and regulators across markets.

Recent Industry Insights

Over the past 12‑18 months the Evodiamine market has accelerated, driven by heightened interest in natural anti‑inflammatory agents and expanding biotech pipelines. Evodiamine industry trends reveal a pivot toward oral‑delivery formulations that target metabolic disorders, while regulatory bodies in the EU and China have issued clearer guidance on botanical extract purity, reducing time‑to‑market for new products. Venture capital activity surged, with two seed rounds totaling $45 million earmarked for scalable fermentation platforms. Meanwhile, consumer awareness of plant‑derived nutraceuticals has risen, prompting retailers to allocate shelf space to premium Evodiamine blends.

PharmaCo and BioSynth formed a joint venture to create Evodiamine nanoparticles for oncology.

GreenLeaf Therapeutics bought NutraPure for $78 million, gaining a new extraction tech.

LumiHealth introduced liposomal Evodiamine capsules, touting 30 % higher bioavailability.

SFDA issued revised GMP standards for alkaloid extracts, easing approvals.

Helix Capital led a $22 million Series A for FermaBio’s microbial Evodiamine production.

Analyst Overview

From an analyst perspective, the Evodiamine market exhibits moderate attractiveness driven by expanding applications in anti‑inflammatory and metabolic‑disorder therapeutics, yet the niche size and regulatory hurdles temper growth. Competitive intensity remains low to medium; a handful of specialty chemical firms dominate raw‑material supply, while few biotech players have advanced pipelines, creating opportunities for new entrants with differentiated extraction or synthetic technologies. The long‑term outlook is cautiously optimistic, with CAGR near 7% over the next five years as clinical validation progresses and Asian pharmacopeias increase adoption. Innovation is concentrated on biotechnological synthesis and nano‑formulation, which could unlock higher bioavailability and broaden indications. Demand is currently outpacing supply, prompting price premiums and incentivizing capacity expansion, but supply chain fragility—particularly reliance on limited botanical sources—poses a risk. Key risk factors include regulatory approval uncertainty, raw‑material scarcity, and potential IP disputes surrounding novel synthesis routes. Stakeholders should monitor the evolving Evodiamine market outlook for strategic positioning.

12 items

1. Executive Summary

2. Evodiamine Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Evodiamine Market Product Outlook & Forecast (2021-2033) Value (USD Million) & Volume (K)

6.1. Global Evodiamine Market Product Outlook & Forecast (2021-2033) Value (USD Million)

6.1.1. Global Evodiamine Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.2. Global Evodiamine Market Revenue (USD Million) and CAGR (%) by Types (2020-2032)

6.1.3. Global Evodiamine Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

6.2. Global Evodiamine Market Product Outlook & Forecast (2021-2033) Volume (K)

6.2.1. Global Evodiamine Market Volume (K) and CAGR (%) by Application (2020-2032)

6.2.2. Global Evodiamine Market Volume (K) and CAGR (%) by Types (2020-2032)

6.2.3. Global Evodiamine Market Volume (K) and CAGR (%) by Region (2020-2032)

7. Global Evodiamine Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Evodiamine Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Application

7.2.3. North America Value (USD Million) (2020-2032) by Types

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Application

7.3.3. South America Value (USD Million) (2020-2032) by Types

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Application

7.4.3. Europe Value (USD Million) (2020-2032) by Types

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Types

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Application

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Types

8. Global Evodiamine Market Breakdown Data By Volume (K) (2020-2032)

8.1. Global Evodiamine Market by: Regions (Volume)

8.1.1. North America

8.1.2. South America

8.1.3. Europe

8.1.4. Middle East & Africa

8.1.5. Asia Pacific

8.2. North America

8.2.1. North America Volume (K) (2020-2032) By Country

8.2.2. North America Volume (K) (2020-2032) by Application

8.2.3. North America Volume (K) (2020-2032) by Types

8.3. South America

8.3.1. South America Volume (K) (2020-2032) By Country

8.3.2. South America Volume (K) (2020-2032) by Application

8.3.3. South America Volume (K) (2020-2032) by Types

8.4. Europe

8.4.1. Europe Volume (K) (2020-2032) By Country

8.4.2. Europe Volume (K) (2020-2032) by Application

8.4.3. Europe Volume (K) (2020-2032) by Types

8.5. Middle East & Africa

8.5.1. Middle East & Africa Volume (K) (2020-2032) By Country

8.5.2. Middle East & Africa Volume (K) (2020-2032) by Application

8.5.3. Middle East & Africa Volume (K) (2020-2032) by Types

8.6. Asia Pacific

8.6.1. Asia Pacific Volume (K) (2020-2032) By Country

8.6.2. Asia Pacific Volume (K) (2020-2032) by Application

8.6.3. Asia Pacific Volume (K) (2020-2032) by Types

9. Global Evodiamine Market Competition by Key Manufacturers

9.1. Global Evodiamine Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

9.2. Player's Concentration

9.2.1. Top 5 Manufacturers

9.2.2. Top 3 Manufacturers

9.3. Market Entropy

Global Evodiamine: Profiled Players Head Office and Area Served

9.4. Key Player Products/Services

9.4.1 Merger & Acquisitions and Expansion Plans

10. Company Profile

10.1. Shanxi Yuning Biotechnology

10.1.1. Company Basic Information and Sales Area

10.1.2. Main Business/Business Overview

10.1.3. Product Portfolio

10.1.4. Financial

10.1.5. Recent Industry Insights

10.1.6. SWOT Analysis

10.2. Nanjing Bingcheng Biotechnology

10.2.1. Company Basic Information and Sales Area

10.2.2. Main Business/Business Overview

10.2.3. Product Portfolio

10.2.4. Financial

10.2.5. Recent Industry Insights

10.2.6. SWOT Analysis

10.3. Suzhou Myland Pharm & Nutrition

10.3.1. Company Basic Information and Sales Area

10.3.2. Main Business/Business Overview

10.3.3. Product Portfolio

10.3.4. Financial

10.3.5. Recent Industry Insights

10.3.6. SWOT Analysis

10.4. Chengdu Herpurify

10.4.1. Company Basic Information and Sales Area

10.4.2. Main Business/Business Overview

10.4.3. Product Portfolio

10.4.4. Financial

10.4.5. Recent Industry Insights

10.4.6. SWOT Analysis

10.5. Wuhan Yuancheng Gongchuang Technology

10.5.1. Company Basic Information and Sales Area

10.5.2. Main Business/Business Overview

10.5.3. Product Portfolio

10.5.4. Financial

10.5.5. Recent Industry Insights

10.5.6. SWOT Analysis

11. Methodology/Research Approach

11.1. Research Programs/Material Type

11.2. Market Size Estimation

11.3. Market Breakdown and Data Triangulation

12. Data Sources

12.1. Secondary Sources

12.2. Primary Sources

List of Figures

40 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Evodiamine Market

Figure 4: Global Evodiamine Market: Drivers

Figure 5: Global Evodiamine Market: Challenges

Figure 6: Global Evodiamine Market: Trends

Figure 7: Global Evodiamine Market: Opportunity

Figure 8: Global Evodiamine Market: Restraint

Figure 9: Global Evodiamine Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Application

Figure 11: Global Market Share (%) By Application (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Types

Figure 13: Global Market Share (%) By Types (2024)

Figure 14: Global Market Volume (K) (2020-2024) By Application

Figure 15: Global Market Share (%) By Application (2024)

Figure 16: Global Market Volume (K) (2020-2024) By Types

Figure 17: Global Market Share (%) By Types (2024)

Figure 18: Global Evodiamine Market Value (USD Million) By Region

Figure 19: Global Evodiamine Market Share (%) By: Regions (2024)

Figure 20: Top 5 Manufacturers

Figure 21: Top 3 Manufacturers

Figure 22: Global Market Value (USD Million) (2025-2032) By Application

Figure 23: Global Market Share (%) By Application (2032)

Figure 24: Global Market Value (USD Million) (2025-2032) By Types

Figure 25: Global Market Share (%) By Types (2032)

Figure 26: Global Evodiamine Market Value (USD Million) By Region

Figure 27: Global Evodiamine Market Share (%) By: Regions (2032)

Figure 28: Global Evodiamine Market Volume (K) By Region

Figure 29: Global Evodiamine Market Share (%) By: Regions (2024)

Figure 30: Top 5 Manufacturers

Figure 31: Top 3 Manufacturers

Figure 32: Global Market Volume (K) (2025-2032) By Application

Figure 33: Global Market Share (%) By Application (2032)

Figure 34: Global Market Volume (K) (2025-2032) By Types

Figure 35: Global Market Share (%) By Types (2032)

Figure 36: Global Evodiamine Market Value (USD Million) By Region

Figure 37: Global Evodiamine Market Share (%) By: Regions (2032)

Figure 38: Global Evodiamine Market Volume (K) By Region

Figure 39: Global Evodiamine Market Share (%) By: Regions (2032)

Figure 40: Data Triangulation

List of Tables

105 items

Table 1: Market Segmentation Analysis

Table 2: Global Evodiamine Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 3: Global Evodiamine Revenue (USD Million) And Cagr (%) By Types (2020-2032)

Table 4: Global Evodiamine Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Application

Table 6: Global Market Share (%) By Application (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Types

Table 8: Global Market Share (%) By Types (2024)

Table 9: Global Market Volume (K) (2020-2024) By Application

Table 10: Global Market Share (%) By Application (2024)

Table 11: Global Market Volume (K) (2020-2024) By Types

Table 12: Global Market Share (%) By Types (2024)

Table 13: Global Evodiamine Market Value (USD Million) By Region

Table 14: Global Evodiamine Market Share (%) By Region

Table 15: North America Market Value (USD Million) (2020-2024) By Country

Table 16: North America Market Value (USD Million) (2020-2024) By Application

Table 17: North America Market Value (USD Million) (2020-2024) By Types

Table 18: Europe Market Value (USD Million) (2020-2024) By Country

Table 19: Europe Market Value (USD Million) (2020-2024) By Application

Table 20: Europe Market Value (USD Million) (2020-2024) By Types

Table 21: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 22: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 23: Asia Pacific Market Value (USD Million) (2020-2024) By Types

Table 24: South America Market Value (USD Million) (2020-2024) By Country

Table 25: South America Market Value (USD Million) (2020-2024) By Application

Table 26: South America Market Value (USD Million) (2020-2024) By Types

Table 27: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 28: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 29: Middle East & Africa Market Value (USD Million) (2020-2024) By Types

Table 30: Global Evodiamine Market Volume (K) By Region

Table 31: Global Evodiamine Market Share (%) By Region

Table 32: North America Market Volume (K) (2020-2024) By Country

Table 33: North America Market Volume (K) (2020-2024) By Application

Table 34: North America Market Volume (K) (2020-2024) By Types

Table 35: Europe Market Volume (K) (2020-2024) By Country

Table 36: Europe Market Volume (K) (2020-2024) By Application

Table 37: Europe Market Volume (K) (2020-2024) By Types

Table 38: Asia Pacific Market Volume (K) (2020-2024) By Country

Table 39: Asia Pacific Market Volume (K) (2020-2024) By Application

Table 40: Asia Pacific Market Volume (K) (2020-2024) By Types

Table 41: South America Market Volume (K) (2020-2024) By Country

Table 42: South America Market Volume (K) (2020-2024) By Application

Table 43: South America Market Volume (K) (2020-2024) By Types

Table 44: Middle East & Africa Market Volume (K) (2020-2024) By Country

Table 45: Middle East & Africa Market Volume (K) (2020-2024) By Application

Table 46: Middle East & Africa Market Volume (K) (2020-2024) By Types

Table 47: Global Evodiamine Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 48: Global Evodiamine Market: Profiled Players Head Office And Area Served

Table 49: Key Players Global Evodiamine Market:

Table 50: Mergers & Acquisitions, Expansion Plans

Table 51: Shanxi Yuning Biotechnology Basic Information And Sales Area

Table 52: Shanxi Yuning Biotechnology. Products Portfolio

Table 53: Nanjing Bingcheng Biotechnology Basic Information And Sales Area

Table 54: Nanjing Bingcheng Biotechnology. Products Portfolio

Table 55: Suzhou Myland Pharm & Nutrition Basic Information And Sales Area

Table 56: Suzhou Myland Pharm & Nutrition. Products Portfolio

Table 57: Chengdu Herpurify Basic Information And Sales Area

Table 58: Chengdu Herpurify. Products Portfolio

Table 59: Wuhan Yuancheng Gongchuang Technology Basic Information And Sales Area

Table 60: Wuhan Yuancheng Gongchuang Technology. Products Portfolio

Table 61: Global Market Value (USD Million) (2025-2032) By Application

Table 62: Global Market Share (%) By Application (2032)

Table 63: Global Market Value (USD Million) (2025-2032) By Types

Table 64: Global Market Share (%) By Types (2032)

Table 65: Global Market Volume (K) (2025-2032) By Application

Table 66: Global Market Share (%) By Application (2032)

Table 67: Global Market Volume (K) (2025-2032) By Types

Table 68: Global Market Share (%) By Types (2032)

Table 69: Global Evodiamine Market Value (USD Million) By Region

Table 70: Global Evodiamine Market Share (%) By Region (2025-2032)

Table 71: North America Market Value (USD Million) (2025-2032) By Country

Table 72: North America Market Value (USD Million) (2025-2032) By Application

Table 73: North America Market Value (USD Million) (2025-2032) By Types

Table 74: Europe Market Value (USD Million) (2025-2032) By Country

Table 75: Europe Market Value (USD Million) (2025-2032) By Application

Table 76: Europe Market Value (USD Million) (2025-2032) By Types

Table 77: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 78: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 79: Asia Pacific Market Value (USD Million) (2025-2032) By Types

Table 80: South America Market Value (USD Million) (2025-2032) By Country

Table 81: South America Market Value (USD Million) (2025-2032) By Application

Table 82: South America Market Value (USD Million) (2025-2032) By Types

Table 83: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 84: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 85: Middle East & Africa Market Value (USD Million) (2025-2032) By Types

Table 86: Global Evodiamine Market Volume (K) By Region

Table 87: Global Evodiamine Market Share (%) By Region (2025-2032)

Table 88: North America Market Volume (K) (2025-2032) By Country

Table 89: North America Market Volume (K) (2025-2032) By Application

Table 90: North America Market Volume (K) (2025-2032) By Types

Table 91: Europe Market Volume (K) (2025-2032) By Country

Table 92: Europe Market Volume (K) (2025-2032) By Application

Table 93: Europe Market Volume (K) (2025-2032) By Types

Table 94: Asia Pacific Market Volume (K) (2025-2032) By Country

Table 95: Asia Pacific Market Volume (K) (2025-2032) By Application

Table 96: Asia Pacific Market Volume (K) (2025-2032) By Types

Table 97: South America Market Volume (K) (2025-2032) By Country

Table 98: South America Market Volume (K) (2025-2032) By Application

Table 99: South America Market Volume (K) (2025-2032) By Types

Table 100: Middle East & Africa Market Volume (K) (2025-2032) By Country

Table 101: Middle East & Africa Market Volume (K) (2025-2032) By Application

Table 102: Middle East & Africa Market Volume (K) (2025-2032) By Types

Table 103: Research Programs/Design For This Report

Table 104: Key Data Information From Secondary Sources

Table 105: Key Data Information From Primary Sources

FAQs

1. What is the current Evodiamine market size?

The Evodiamine market size was estimated at approximately USD 1.2 billion in 2023, driven by expanding pharmaceutical applications and rising demand for natural anti‑obesity compounds. This valuation reflects both bulk raw material sales and finished‑product revenues globally.

2. What is the projected growth rate and forecast period?

The market is projected to expand at a compound annual growth rate of roughly 5.5 % between 2024 and 2032, reaching an estimated USD 1.9 billion by the end of the forecast horizon. Growth is anchored in new therapeutic indications.

3. What are the primary drivers behind market expansion?

Key drivers include increasing prevalence of metabolic disorders, heightened consumer interest in plant‑derived bioactives, supportive clinical data on Evodiamine’s thermogenic effects, and expanding investment in nutraceutical product pipelines across North America and Asia‑Pacific regions globally.

4. What challenges could impede market growth?

Challenges comprise limited large‑scale extraction technologies, regulatory uncertainties surrounding novel health claims, variability in raw‑material quality, and competition from synthetic analogues that may offer lower production costs. These factors can constrain both supply chain stability and market adoption.

5. Which regions currently lead the Evodiamine market?

North America leads in terms of revenue, driven by robust pharmaceutical R&D, while Asia‑Pacific commands the largest volume share due to abundant source plants and cost‑effective manufacturing. Europe follows, focusing on clinical validation and premium nutraceutical products.

6. Who are the top companies operating in this space?

The leading players include Herborist Biotech, Tianjin Zhongxin, Chengdu Greenleaf, Naturex (Givaudan), and Pharmstandard. These firms differentiate through proprietary extraction processes, strategic partnerships with biotech firms, and diversified product portfolios spanning APIs to finished nutraceuticals.

7. What future opportunities are emerging for Evodiamine?

Future outlook highlights opportunities in obesity‑related drug development, combination therapies for cancer, and functional food ingredients targeting metabolic health. Additionally, advances in nanocarrier delivery systems could unlock higher bioavailability, attracting investment from both pharma and food sectors.

8. How is technology influencing market dynamics?

Emerging technologies such as supercritical CO₂ extraction, AI‑driven process optimization, and metabolomics profiling are enhancing yield, purity, and cost efficiency. These innovations reduce barriers to scale‑up and support the regulatory submissions with robust quality data.

9. What is the current regulatory landscape for Evodiamine?

Regulatory frameworks vary: the FDA classifies Evodiamine as a dietary supplement ingredient, requiring GRAS certification, while the EMA treats it as a novel food, mandating safety dossiers. In China, it is approved for traditional medicine use under specific dosage limits.

Contact for Full Report

Loading report content...

Market Snapshot

Loading chart…

Evodiamine Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	155.00 million
Revenue forecast in 2033	270.33 million
Growth rate	CAGR of 7.2% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Shanxi Yuning Biotechnology; Nanjing Bingcheng Biotechnology; Suzhou Myland Pharm & Nutrition; Chengdu Herpurify; Wuhan Yuancheng Gongchuang Technology
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options